Finanzas de BioNexus Gene Lab Corp (BGLC)BGLCBioNexus Gene Lab Corp

BioNexus Gene Lab Corp (BGLC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Chemrex, accounting for 99.9% of total sales, equivalent to $2.13M. Another important revenue stream is BioNexus Malaysisa. Understanding this composition is critical for investors evaluating how BGLC navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, BioNexus Gene Lab Corp maintains a gross margin of 17.05%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -398.69%, while the net margin is -376.14%. These profitability ratios, combined with a Return on Equity (ROE) of -33.66%, provide a clear picture of how effectively BGLC converts its operational activities into shareholder value.

In the context of the broader market, BGLC competes directly with industry leaders such as EHGO and CAPS. With a market capitalization of $2.43M, it holds a leading position in the sector. When comparing efficiency, BGLC's gross margin of 17.05% stands against EHGO's 15.14% and CAPS's 27.93%. Such benchmarking helps identify whether BioNexus Gene Lab Corp is trading at a premium or discount relative to its financial performance.

The company has reported consistent losses, with a net income of -286,451 USD in Q2 2026 and a gross margin of 17.05%. The forward P/E ratio is 0, indicating no expected earnings growth in the near term.